Profound Medical Q1 2024 GAAP EPS $(0.26) Beats $(0.30) Estimate, Sales $1.910M Miss $2.521M Estimate
Profound Medical Q1 2024 GAAP EPS $(0.26) Beats $(0.30) Estimate, Sales $1.910M Miss $2.521M Estimate
Profound Medical 2024年第一季度GAAP每股收益美元（0.26美元）超過預期（0.30美元），銷售額19.1萬美元低於2521萬美元的預期
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.910 million which missed the analyst consensus estimate of $2.521 million by 24.24 percent. This is a 2.69 percent increase over sales of $1.860 million the same period last year.
Profound Medical（納斯達克股票代碼：PROF）公佈的季度虧損爲每股0.26美元，比分析師普遍預期的0.30美元（0.30美元）高出13.33％。這比去年同期每股虧損0.32美元（0.32美元）增長了18.75％。該公司公佈的季度銷售額爲19.1億美元，比分析師普遍預期的2521萬美元低24.24％。這比去年同期的18.6億美元銷售額增長了2.69％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。